Harmony Biosciences preannounces record second quarter 2026 revenue of $261 million, reaffirming full-year guidance.

Harmony Biosciences preannounced preliminary second quarter 2026 net product revenue of approximately $261 million, a 30% increase year-over-year. The company reaffirmed its full-year 2026 net product revenue guidance and announced a CFO transition.

Key Highlights

• Preliminary second quarter net product revenue for WAKIX reached a record of approximately $261 million, up 30% from the prior year.
• Full-year 2026 net product revenue guidance was reaffirmed at a range of $1.0 billion to $1.04 billion.
• The company announced that Chief Financial Officer Glenn Reicin has stepped down, effective July 16, 2026, with SVP and Controller Stephen Mollichella appointed as Interim Principal Financial Officer.